Comprehensive Characterization of Androgen-Responsive lncRNAs Mediated Regulatory Network in Hormone-Related Cancers

Figure 3

The validation of androgen-responsive lncRNAs in LNCaP cells. (a–c) RT-PCR analyses of lnc-FAM105A-2, AC003090.1, and RP11-31E13.2’s expressions in LNCaP cells treated with DHT for 24 h in dose series of 0 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, and 1000 nM. Values of expressions treated with equal volume of vehicle were used as control. (d–f) RT-PCR analyses of lnc-FAM105A-2, AC003090.1, and RP11-31E13.2’s expressions in LNCaP cells treated with 10 nM DHT in time series of 0 h, 2 h, 8 h, 24 h, and 48 h. Values of expressions treated with equal volume of vehicle in the same time series were used as control. (g–i) Genome browser view of the AC003090.1, RP11-31E13.2, and lnc-FAM105A-2 genomic locus for AR ChIP-seq data tracks obtained from VCaP cells treated with either vehicle or dihydrotestosterone (DHT) alone or combinations including DHT+Bicalutamide. Significant AR binding observed in each data track are represented as peaks. (j) The expressions of lnc-FAM105A-2 and AC003090.1 and RP11-31E13.2 after AR knockdown compared with NC in LNCaP cells. (k–m) The expressions of lnc-FAM105A-2, AC003090.1, and RP11-31E13.2, after AR knockdown in LNCaP cells with or without DHT treatment. Results are presented as the of three independent experiments. Significance was defined as (, , and ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)